Please find attached outcome of the Board Meeting held on January 21, 2022 With reference to the captioned subject and Observation Letters dated April 22, 2022 issued by National Stock Exchange of India Limited and BSE Limited and as directed by Hon'ble National Company Law Tribunal, Mumbai ('NCLT') vide their Order dated June 6, 2022, the Company has hosted on its website https://www.hdfclife.com/about-us/investor-relations an 'abridged prospectus' prepared in line with the format prescribed under 'Part E' of Schedule VI of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, for information of the stakeholders. (As Per BSE Announcement dated on 30.06.2022) This is to inform that the Hon'ble National Company Law Tribunal ('NCLT'), Mumbai Bench, vide hearing convened on September 16, 2022 has sanctioned the Scheme of Amalgamation ('Scheme') between Exide Life Insurance Company Limited ('Transferor Company / 'Wholly-owned subsidiary'), into HDFC Life Insurance Company Limited ('Transferee Company / 'Holding Company'), under Sections 230 to 232 of the Companies Act, 2013. (As Per BSE Announcement dated on 16.09.2022) We further wish to inform you that the Insurance Regulatory and Development Authority of India vide its letter dated October 13, 2022, has provided its final approval to the Scheme in accordance with Insurance Regulatory and Development Authority (Scheme of Amalgamation and Transfer of Life Insurance Business) Regulations, 2013. (As Per BSE Announcement Dated on 13.10.2022)